[1] 胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220. [2] 胡大一, 韩雅玲, 孙艺红, 等. 替罗非班在冠状动脉粥样硬化性心脏病治疗的中国专家共识[J]. 中华内科杂志, 2013,52(5):434-439. [3] 郭世杰, 齐向前. 糖皮质激素和(或)免疫球蛋白治疗替罗非班诱导重度血小板减少症的临床观察[J]. 临床心血管病杂志, 2021, 37(5): 417-420. [4] The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty [J]. Circulation, 1997, 96(5): 1445-1453. [5] LO G K, JUHL D, WARKENTIN T E, et al. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings[J]. J Thromb Haemost, 2006, 4(4): 759-765. [6] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. [7] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志:中英文, 2024, 32(7): 603-700. [8] SCHULMAN S, KEARON C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients[J]. J Thromb Haemost, 2005, 3(4): 692-694. [9] SCHULMAN S, KEARON C, KAKKAR A K, et a1. Extended use of dabigatran,warfarin, or placebo in venous thrombnembolism[J]. N Engl J Med, 2013, 368(8):709-718. [10] 李红, 贾若飞, 贺建勋, 等. 替罗非班诱导血小板减少症临床观察及干预分析[J]. 中国介入心脏病学杂志, 2019, 27(5): 265-270. |